AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02404454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autocross-linked acid hyaluronic gel
Description: Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
Study NCT02404454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office second look hysteroscopy
Description: Second-look hysteroscopy after three months
Study NCT03174067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: The participant receives buprenorphine
Study NCT02329041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath Series 5
Description: one kind of videolaryngoscopes, which are widely used in airway management.
Study NCT02329041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: another kind of videolaryngoscopes, which are also widely used in airway management.
Study NCT02950194 — intervention group
Intervention type: PROCEDURE
Intervention: PPAWI
Description: One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
Study NCT00030381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4'-iodo-4'-deoxydoxorubicin
Description: Given IV
Study NCT00030381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00315055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, Intramuscular (IM)
Study NCT00315055 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//PRP~T combined
Description: 0.5 mL, IM
Study NCT00315055 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: 0.5 mL, IM
Study NCT00909766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study NCT04395755 — intervention group
Intervention type: BEHAVIORAL
Intervention: Generalized Anxiety Disorder-7 (GAD-7)
Description: The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
Study NCT04395755 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Health Questionnaire-9 (PHQ-9)
Description: The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
Study NCT00219739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 600 mg
Study NCT00496379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZK219477
Description: Given intravenously over approximately 30 minutes once every 3 weeks
Study NCT02287649 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Study NCT01704846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 120 mg capsule
Description: 1capsule of BI 201335 NA 120 mg capsule
Study NCT01704846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 120 mg capsule
Description: 1 capsule of BI 201335 NA 120 mg capsule
Study NCT00454064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral treatment
Study NCT00219739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg + Peg-Interferon
Study NCT03323229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Enhanced communications & ultrasound
Description: Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (\<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
Study NCT01213433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine
Description: Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
Study NCT02600026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DriveCam
Description: Video event monitoring device
Study NCT02600026 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DriveCam
Description: Video event monitoring device
Study NCT02600026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Video feedback intervention
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.1 mg, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.2 mg, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.4 mg, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.8 mg, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.8 mg with titration, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 1.6 mg with titration, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.1 mg, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.2 mg, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.4 mg, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.8 mg with titration, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.6 mg, once weekly, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg with titration, once daily, s.c. injection
Study NCT00696657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg with titration, once daily, s.c. injection
Study NCT03174067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: The participant receives clonidine
Study NCT03639402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education classes
Description: Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
Study NCT01766687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydration
Study NCT00937105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A contact lenses
Description: FDA approved soft contact lenses
Study NCT00937105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renu Multiplus
Study NCT00937105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care
Study NCT00219739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg + Cytarabine
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo solution
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Study NCT00734474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01041326 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
Study NCT01041326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
Study NCT01130675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caffeinated coffee
Description: 8 oz. of caffeinated cofee/breakfast\&noon meal. No intervention for 2nd arm.
Study NCT03740633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: passive ankle pump motions on the day of surgery
Description: Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.
Study NCT03740633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery
Description: Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.
Study NCT03740633 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
Study NCT03740633 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regular care
Description: Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
Study NCT03056404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Study NCT03056404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory functional exploration
Study NCT02050243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5ALA
Description: 20mg/kg of oral suspension of 5ALA
Study NCT02513342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar 30mg continuous intravenous injection pump,d1-d7；
Study NCT02513342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: d4 Docetaxel，75（mg/m2），iv；
Study NCT02513342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: d4 Docetaxel，75（mg/m2），iv；
Study NCT02513342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: d4，cisplatin，75（mg/m2），iv；
Study NCT02513342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: d4，cisplatin，75（mg/m2），iv；
Study NCT01704846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 40 mg capsule
Description: 3 capsules of BI 201335 NA 40 mg capsule
Study NCT00678158 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy
Description: Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
Study NCT02874261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Periodic Acceleration
Description: oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
Study NCT01265758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
Study NCT01265758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
Study NCT02104752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 360 mg/day (divided into twice daily oral doses)
Study NCT02104752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive, matched placebo (Sugar Pill)
Study NCT01432158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: This vaccine will be given to healthy adults without prior pneumococcal vaccination.
Study NCT00912015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol OAD
Study NCT01432158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax II
Description: This vaccine will be given to healthy adults without prior pneumococcal vaccination.
Study NCT04242758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: SGLT2-inhibitor: Diabetic oral drug with diuretic properties
Study NCT04242758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5mg
Description: Best known thiazide class diuretic.
Study NCT04101123 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT01268345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood glucose monitor
Description: Blood glucose monitor is used to monitor the blood glucose level of the human-being
Study NCT01268345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blood glucose monitor
Description: Blood glucose monitor is used to monitor the blood glucose level of the human-being.
Study NCT00664846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin / Clopidogrel, Atorvastatin / Simvastatin
Description: Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
Study NCT00664846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asprin / Clopidogrel, Atorvastatin / Simvastatin
Description: Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
Study NCT03907007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous electrical nerve stimulation
Description: Stimulation and medication at the same instant
Study NCT03907007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous electrical nerve stimulation
Description: Stimulation is given without administering medication
Study NCT02242162 — intervention group
Intervention type: PROCEDURE
Intervention: phrenic nerves magnetic stimulations
Study NCT02210702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol 35mcg/Norethindrone 1mg
Study NCT02210702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol 20mcg/Norethindrone 1mg
Study NCT00779571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crispbread
Description: 8 week low calorie diet
Study NCT00779571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crispbread
Description: 8 week low calorie diet
Study NCT03613129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT38
Description: Infusion
Study NCT00857480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous administration of 2 mg NRL972
Study NCT00857480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
Study NCT00857480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
Study NCT03594331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose PvP001
Description: Low-dose PvP001
Study NCT03594331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose PvP001
Description: Medium-dose PvP001
Study NCT03594331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose PvP001
Description: High-dose PvP001
Study NCT03594331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mL liquid with no drug
Study NCT00280033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Provided in vials that contain 0.8 mL volume per vial.
Study NCT00280033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (Chiron)
Description: Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
Study NCT00280033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
Study NCT00280033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo.
Study NCT02873676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
Study NCT02873676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training program
Description: The training program involve warm-up exercise, muscle strength training and relaxing
Study NCT02873676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification project
Description: Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
Study NCT02873676 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: The intervention involve dietary pattern modification and protein intake standardization
Study NCT04310579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone and Midazolam
Description: In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day.